Junji Furuse
A5056197140- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Lung Cancer Research Studies
- Fibroblast Growth Factor Research
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Liver Disease Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Hepatitis B Virus Studies
- Liver physiology and pathology
- Cancer Immunotherapy and Biomarkers
- Pancreatitis Pathology and Treatment
- Genetic factors in colorectal cancer
- Oral and gingival health research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Eosinophilic Disorders and Syndromes
Kyorin University
2016-2025
Kanagawa Cancer Center
2007-2025
Kanagawa Prefectural Hospital Organization
2020-2025
National Cancer Center
2020-2025
National Cancer Center Hospital East
2006-2023
Kyorin University Hospital
2011-2023
Hudson Institute
2020-2022
Japan Breast Cancer Research Group
2015-2021
Tochigi Cancer Center
2009-2020
Shizuoka Cancer Center
2007-2020
BackgroundA single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial unresectable hepatocellular carcinoma.MethodsIn this global, open-label, 3 trial, the majority patients we enrolled with carcinoma no previous systemic treatment were randomly assigned...
A British randomised study of gemcitabine plus cisplatin (GC) combination showed promising results in biliary tract cancer (BTC) patients. In our study, we evaluated the efficacy and safety this compared with alone (G) Japanese BTC
Purpose The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority gemcitabine plus compared with respect overall survival. Patients Methods participants were chemotherapy-naive patients locally advanced or metastatic pancreatic cancer. randomly assigned receive only (1,000 mg/m 2 on days 1, 8, 15 a 28-day cycle), (80, 100, 120 mg/d according body-surface area 1 through 28 42-day (gemcitabine 1,000 8 60, 80, 100 14 21-day cycle). Results In total...
This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint pre-treatment before initial TACE.Patients unresectable hepatocellular carcinoma (HCC) were randomised to (n=80) or (n=76). Patients in combination group received 400 mg once daily for 2-3 weeks TACE, followed by 800 during on-demand conventional sessions until time untreatable (unTACEable) progression (TTUP), defined as tumour...
<h3>Importance</h3> Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for treatment of advanced hepatocellular carcinoma. <h3>Objective</h3> To assess efficacy everolimus in patients with carcinoma whom sorafenib failed. <h3>Design, Setting, and Participants</h3> EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults Barcelona Clinic Liver Cancer stage B or C Child-Pugh A liver function whose disease progressed during after...
A randomized, controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S-1 with upfront surgery for patients planned resection of pancreatic cancer. Patients were enrolled after the diagnosis resectable or borderline by portal vein involvement cancer histological confirmation. They randomly assigned either surgery. Adjuvant was administered 6 months curative who fully recovered within 10 weeks in both arms. The primary endpoint is overall survival; secondary...
Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). In our retrospective analysis, we studied the immunobiology potential associations between biomarkers outcomes nivolumab HCC.Fresh archival tumour samples from dose-escalation dose-expansion phases of CheckMate 040 trial were analysed by immunohistochemistry RNA sequencing assess several inflammatory gene...
379 Background: A single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the STRIDE (Single Regular Interval D) regimen, formerly T300+D, showed encouraging clinical activity and limited toxicity a phase 2 uHCC study (Study 22, NCT02519348), suggesting exposure is sufficient improve upon activity. HIMALAYA (NCT03298451) evaluated efficacy safety or vs sorafenib (S) uHCC. Methods: an open-label, multicenter, 3 study, which pts with no prior systemic therapy were initially...
Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with poor prognosis. Futibatinib, next-generation, covalently binding FGFR1-4 inhibitor, has been shown to both antitumor activity patients FGFR-altered tumors and strong preclinical against acquired resistance mutations associated ATP-competitive FGFR inhibitors.In this multinational, open-label, single-group, phase study, we enrolled...
The carcinoembryonic antigen glypican-3 (GPC3) is an ideal target of anticancer immunotherapy against hepatocellular carcinoma (HCC). In this nonrandomized, open-label, phase I clinical trial, we analyzed the safety and efficacy GPC3 peptide vaccination in patients with advanced HCC.Thirty-three HCC underwent (intradermal injections on days 1, 15, 29 dose escalation). primary endpoint was vaccination. secondary endpoints were immune response, as measured by IFN-γ ELISPOT assay, outcomes...
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) the digestive system. Clinical data from 258 patients with unresectable or recurrent NEC gastrointestinal tract (GI) hepato-biliary-pancreatic system (HBP), who received chemotherapy, were collected 23 Japanese institutions and retrospectively. Patients had primary sites in esophagus (n = 85), stomach 70), small bowel 6), colorectum 31), hepato-biliary 31) pancreas 31). Median overall survival...
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety sorafenib patients unresectable HCC real-life practice, including Child-Pugh B who were excluded from clinical trials.Patients HCC, for whom decision treat sorafenib, based on approved label prescribing guidelines, had been taken by their physician, eligible inclusion. Demographic data...